Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | CCR8 | P51685 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11825124 | 0.97 | CCR1 (0.48) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL13328096 | 0.87 | CCR1 (0.75) | CCR1CCR5CCR8KDM4ELMNA | |
| Dipyridyl SCHEMBL27618154 | 0.83 | KDM4E (0.54) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL9014297 | 0.83 | CCR1 (0.38) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL169671 | 0.83 | CCR1 (0.62) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL28267135 | 0.83 | CCR1 (0.41) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL9014352 | 0.83 | CCR1 (0.38) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL17212957 | 0.82 | CCR1 (0.45) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL13621091 | 0.82 | SLC40A1 (0.42) | CCR1CCR5CCR8KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL27825233 | 0.82 | CCR1 (0.61) | CCR1CCR5CCR8KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12628491-B2 | Organic-inorganic adhesion layer and its use in perovskite solar cells and modules | Tandem PV (US) | 2026-05-12 | — | — | US | claimed |
| WO-2025217208-A1 | CHEMICAL MECHANICAL PLANARIZATION POLISHING FOR INTERCONNECTS DIFFUSION BARRIER MATERIALS | VERSUM MATERIALS US, LLC (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | claimed |
| CN-120059137-A | Method for preparing high-transition metal content catalyst by vacuum-assisted permeation method | 三峡大学 | 2025-05-30 | — | — | CN | claimed |
| CN-116272969-B | Catalyst for synthesizing hexamethylenediamine and preparation method thereof | 中国科学院长春应用化学研究所 | 2025-03-07 | — | — | CN | claimed |
| CN-119569558-A | Method for synthesizing 2-phenylpropionic acid by nickel-catalyzed reaction of styrene and carbon dioxide | 中国石油化工股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-118084824-A | Synthesis method of antidepressant drug, namely voethidine | 万特制药(海南)有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117924215-A | Synthesis method of vothixetine | 万全万特制药（厦门）有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2024081751-A1 | ORGANIC-INORGANIC ADHESION LAYER AND ITS USE IN PEROVSKITE SOLAR CELLS AND MODULES | Tandem PV (US) | 2024-04-18 | — | — | WO | claimed |
| US-20240121970-A1 | ORGANIC-INORGANIC ADHESION LAYER AND ITS USE IN PEROVSKITE SOLAR CELLS AND MODULES | Tandem PV | 2024-04-11 | — | — | US | claimed |
| US-5157032-A | Spectroscopically or photoactively determinable | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-10-20 | — | — | US | claimed |
| WO-1992014741-A1 | MONO, BIS OR TRIS (2,2'-SUBSTITUTED BIPYRIDINE) COMPLEXES OF A METAL SELECTED AMONGST IRON, RUTHENIUM, OSMIUM OR VANADIUM AND PREPARATION METHODS THEREOF | ASULAB S.A. (CH) | 1992-09-03 | — | — | WO | claimed |
| US-5112974-A | Targets tumor cells for radiation treatment, metal complexes with amines or imines | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1992-05-12 | — | — | US | claimed |
| US-4980473-A | Cobalt or ruthenium complexes of 1,10-phenanthroline or derivatives | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1990-12-25 | — | — | US | claimed |
| US-4721669-A | METAL 1,10-PHENANTHROLINE COMPLEXES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1988-01-26 | — | — | US | claimed |
| US-4699978-A | LABELING OR NICKING DNA WITH PHENANTHROLINE COORDINATION COMPLEX | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1987-10-13 | — | — | US | claimed |
| EP-0211043-A1 | CHEMICAL PROBES FOR LEFT-HANDED DNA AND CHIRAL METAL COMPLEXES AS Z-SPECIFIC ANTITUMOR AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0210232-A1 | SITE-SPECIFIC RUTHENIUM(II) AND COBALT(III) ANTITUMOR AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004358-A1 | SITE-SPECIFIC RUTHENIUM(II) AND COBALT(III) ANTITUMOR AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 1986-07-31 | — | — | WO | claimed |
| WO-1986004244-A1 | CHEMICAL PROBES FOR LEFT-HANDED DNA AND CHIRAL METAL COMPLEXES AS Z-SPECIFIC ANTITUMOR AGENTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) | 1986-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12628491-B2 | Organic-inorganic adhesion layer and its use in perovskite solar cells and modules | EPCAM, CDH1, L1CAM | CCR1 2140/4885CCR5 3549/4885CCR8 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.